• Lyonbiopole
  • Lyonbiopole missions
  • The Lyonbiopole team
  • Governance
    • Board of Directors
    • Members of the Board
  • The technical group, Gtech
  • Our public funders
  • Our members and associated members
  • Press area
    • Press releases
    • Communication tools
    • Mobile app
  • Become a member
  • Contact us
• Research and innovation
  • Goals
  • R&D project support
    • Setting up and funding a project
    • Project accreditation
    • Supporting a European project
    • Project monitoring
  • Scientific coordination
    • Partnering Day
    • The Microbiota and Health Day
    • Workshops and topicaldays
  • Project funding
    • Lyonbiopole actions
    • Calls for projects
  • Clinical innovation
  • Structuring program
    • MabDesign
  • Upcoming events
• Economic development
  • Goals
  • Private investment
    • Private Inv€stments Day
    • Inv€stor Meetings
  • Access to skills
    • GPEC and training initiatives
    • Intellectual property and consortium agreements
  • Networking
    • Lunch Break Partnering
    • Open Innovation Meetings
    • Life science directory
  • Upcoming events
• International
  • Goals
  • Europe
    • The support offer to Europe
    • Main European funding
    • Our clusters partners
    • Our European projects
  • International funding tools
    • The International Representation and Expertise Programme – IREP
    • ITPP
    • Cooperation with the CQDM
  • Our international trade missions
  • Upcominig events
• Facilities
  • Our labs offer
  • Our offices offer
  • Contact-us
• Directories
  • Companies
  • Consultants & Service providers
  • Research units
  • Healthcare institutions
  • Collaborative Clinical Research Structures
  • R&D projects
• Diary – News
  • Upcoming events
    • All events
    • Our events
    • In partnership
    • Around our themes
  • News
    • All news
    • Lyonbiopole
    • Our members
    • Focus on
    • New members
    • Blog
  • Newsletter
  • Lyonbiopole in action

Transgene (Euronext Paris: TNG), a company  focused on designing and developing targeted  immunotherapies for the treatment of cancer and  infectious diseases, today announced  that the first patient  has been included in the  multiple dose  cohort of the Phase1/1b trial with TG1050, Transgene’s immunotherapy product candidate for the  treatment of chronic hepatitis B virus (HBV) infection (NCT: 02428400).